Queensland Bauxite to develop 'game-changing' cannabis pill
By administrator | 16 January 2018
THE medical cannabis subsidiary of Queensland Bauxite (ASX: QBL) has signed a landmark deal with a Canadian company to develop a new cannabis pill, one which doctors will be able to recommend and officially prescribe to patients.
Queensland Bauxite's VitaCann division says the pill will be the first of its kind; a pharmaceutical-grade cannabis medicine which doctors will likely be more willing to prescribe than the drug's smoked alternative.
The company came out of a trading halt this morning to announce plans for the medication which it will develop in a joint venture with Toronto-based pharmaceutical company Canntab Therapeutics.
Following the announcement, QBL shares surged more than 71 per cent to trade at $0.089 at the time of writing (10:17am AEST).
There is currently no pharmaceutical-grade cannabis medicine yet available for doctors to prescribe anywhere in the world, however high-THC smoked marijuana is available in countries with health department exemptions including the United States, Canada and Israel.
VitaCann believes the new product could be a market disruptor. Read more
Paris Faint - Business News Australia - 9 Jan 2018
Comments
Your email address will not be published.
We welcome relevant, respectful comments.